Born to Kill: NK Cells Go to War against Cancer
- 1 March 2019
- journal article
- editorial
- Published by Elsevier in Trends in Cancer
- Vol. 5 (3) , 143-145
Abstract
No abstract availableKeywords
Funding Information
- U. S. Department of Defense (W81XWH-17-1-0029)
- Breast Cancer Research Program (BC180476P1)
- Department of Radiation Oncology
- Lytix
- Phosplatin
- Phosplatin
- Luke Heller TECPR2 Foundation
- SOTIO
This publication has 13 references indexed in Scilit:
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer VaccinesCell, 2018
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsCell, 2018
- The hallmarks of successful anticancer immunotherapyScience Translational Medicine, 2018
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunityScience, 2018
- IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activityNature, 2017
- Trial Watch: Adoptively transferred cells for anticancer immunotherapyOncoImmunology, 2017
- Control of Metastasis by NK CellsCancer Cell, 2017
- Soluble NKG2D ligands limit the efficacy of immune checkpoint blockadeOncoImmunology, 2017
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodiesBlood, 2014